ASCO GU 2008 - Brachytherapy: More Is Better

Main Category: Urology / Nephrology
Also Included In: Radiology / Nuclear Medicine
Article Date: 16 Feb 2008 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:4 stars

4 (1 votes)

Healthcare Prof:4 and a half stars

4.5 (2 votes)


UroToday.com - A survey in 2002 reported that half of urologists in the US offer brachytherapy. The concept of radiation guidance can be either giving radiotherapy via beam or needles. He argued that prostate IG-HDR delivers high doses to the prostate and not the rectum or urethra. He presented a 5-week hyperfractionated protocol of EBRT and HDR boost. The 5-year outcomes of 267 patients treated with high doses revealed the biochemical control is 90%, compared to 68.7% for low dose. Overall survival at 5 years was better with the high dose combination. The mean dose delivered is 77Gy in the ART group which is higher than the 68Gy in the ERBT group. The HDR prostate bed dose was biologically much higher. Patients receiving HDR boost do better regarding 10 survival results with 76% having biochemical freedom from disease. The distant metastatic rate of HDR is also less than ERBT + ART.

In a study evaluating HDR alone compared to HDR + ADT it was found that there was no benefit to the combined therapy. In those with poor prognostic factors, the patients receiving ADT and HDR had worse survival, which was surprising. This has prompted a 3 arm study of XRT alone, XRT + ADT for duration of 24 months and XRT + ADT + boost. Thus HDR using >210Gy dose delivered to the prostate bed results in a survival benefit at 5 and 10 years.

Presented by Alvaro Martinez at the American Society of Clinical Oncology (ASCO) - 2008 Genitourinary Cancers Symposium - A Multidisciplinary Approach - February 14-16, 2008 San Francisco, California, USA

Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS Professor & Chairman Department of Urology University of California, Davis, School of Medicine Sacramento, CA

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

----------------------------
Copyright © 2007 - UroToday
Reproduced for Medical News Today with permission of UroToday.
----------------------------

Article adapted by Medical News Today from original press release.
Visit our urology / nephrology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Urology Today. "ASCO GU 2008 - Brachytherapy: More Is Better." Medical News Today. MediLexicon, Intl., 16 Feb. 2008. Web.
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/97592.php>

APA
Urology Today. (2008, February 16). "ASCO GU 2008 - Brachytherapy: More Is Better." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/97592.php.

Please note: If no author information is provided, the source is cited instead.


Urology / Nephrology

Most Popular Articles



Follow Our Urology News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Urology / Nephrology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »